nach oben

03.02.2020 | Herzinsuffizienz | CME

Diagnostik und Therapie der chronischen Herzinsuffizienz

Update 2020

verfasst von: Prof. Dr. Gülmisal Güder, Prof. Dr. Georg Ertl, Prof. Dr. Christiane E. Angermann

Erschienen in: Herz

Einloggen, um Zugang zu erhalten

Zusammenfassung

Herzinsuffizienz ist eine Systemerkrankung. Mit steigendem Alter der Bevölkerung nehmen weltweit ihre Prävalenz sowie die Bedeutung von Komorbiditäten für die Symptomatik, Krankheitsprogression und Prognose zu. Seit der letzten Version der europäischen Leitlinien zur Diagnostik und Therapie der Herzinsuffizienz 2016 wurden vielversprechende neue Medikamente sowie neue Device-basierte Monitoring- und Behandlungsoptionen verfügbar. Das immer breitere Spektrum diagnostischer und therapeutischer Möglichkeiten macht andererseits die Herzinsuffizienzbehandlung immer komplexer. Dieser Übersichtsartikel soll eine praxisnahe Hilfestellung bieten für die Versorgung herzinsuffizienter Patienten gemäß aktueller Evidenzlage.

Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. https://doi.org/10.1093/eurheartj/ehw128 CrossRef

Stork S, Handrock R, Jacob J et al (2017) Epidemiology of heart failure in Germany: a retrospective database study. Clin Res Cardiol 106(11):913–922. https://doi.org/10.1007/s00392-017-1137-7 CrossRef

Pieske B, Tschope C, de Boer RA et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. https://doi.org/10.1093/eurheartj/ehz641 CrossRef

Seferovic PM, Ponikowski P, Anker SD et al (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1531 CrossRef

Gallagher J, McCormack D, Zhou S et al (2019) A systematic review of clinical prediction rules for the diagnosis of chronic heart failure. ESC Heart Fail 6(3):499–508. https://doi.org/10.1002/ehf2.12426 CrossRef

Reddy YNV, Carter RE, Obokata M et al (2018) A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138(9):861–870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646 CrossRef

Emdin M, Aimo A, Rapezzi C et al (2019) Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz298 CrossRef

Muntze J, Gensler D, Maniuc O et al (2019) Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharmacol Ther 105(5):1224–1233. https://doi.org/10.1002/cpt.1321 CrossRef

Aizpurua AB, Wijk SS, Rocca HB et al (2019) Validation of the HFA-PEFF-score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1614 CrossRef

10.

Triposkiadis F, Butler J, Abboud FM et al (2019) The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J 40(26):2155–2163. https://doi.org/10.1093/eurheartj/ehz158 CrossRef

11.

Lund LH, Claggett B, Liu J et al (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20(8):1230–1239. https://doi.org/10.1002/ejhf.1149 CrossRef

12.

Solomon SD, Claggett B, Lewis EF et al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37(5):455–462. https://doi.org/10.1093/eurheartj/ehv464 CrossRef

13.

Solomon SD, McMurray JJV et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa1908655 CrossRef

14.

Cleland JGF, Bunting KV, Flather MD et al (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26–35. https://doi.org/10.1093/eurheartj/ehx564 CrossRef

15.

Ghimire A, Fine N, Ezekowitz JA, Howlett J, Youngson E, McAlister FA (2019) Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. Eur Heart J 40(26):2110–2117. https://doi.org/10.1093/eurheartj/ehz233 CrossRef

16.

Halliday BP, Wassall R, Lota AS et al (2019) Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 393(10166):61–73. https://doi.org/10.1016/S0140-6736(18)32484-X CrossRef

17.

Maggioni AP, Anker SD, Dahlstrom U et al (2013) Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15(10):1173–1184. https://doi.org/10.1093/eurjhf/hft134 CrossRef

18.

Mullens W, Damman K, Harjola VP et al (2019) The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137–155. https://doi.org/10.1002/ejhf.1369 CrossRef

19.

Brisco-Bacik MA, Ter Maaten JM, Houser SR et al (2018) Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc 7(18):e9149. https://doi.org/10.1161/JAHA.118.009149 CrossRef

20.

Gilotra NA, Princewill O, Marino B et al (2018) Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail 6(1):65–70. https://doi.org/10.1016/j.jchf.2017.10.001 CrossRef

21.

Group CTS (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316(23):1429–1435. https://doi.org/10.1056/NEJM198706043162301 CrossRef

22.

McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077 CrossRef

23.

Velazquez EJ, Morrow DA, DeVore AD et al (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380(6):539–548. https://doi.org/10.1056/NEJMoa1812851 CrossRef

24.

Wachter R, Senni M, Belohlavek J et al (2019) Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 21(8):998–1007. https://doi.org/10.1002/ejhf.1498 CrossRef

25.

Rosano GMC, Tamargo J, Kjeldsen KP et al (2018) Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 4(3):180–188. https://doi.org/10.1093/ehjcvp/pvy015 CrossRef

26.

Gerhardt LMS, Angermann CE (2019) Hyperkalemia—pathophysiology, prognostic significance and treatment options. Dtsch Med Wochenschr 144(22):1576–1584. https://doi.org/10.1055/a-0762-8244 CrossRef

27.

von Haehling S, Ebner N, Evertz R et al (2019) Iron deficiency in heart failure: an overview. JACC Heart Fail 7(1):36–46. https://doi.org/10.1016/j.jchf.2018.07.015 CrossRef

28.

Lewis GD, Malhotra R, Hernandez AF et al (2017) Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 317(19):1958–1966. https://doi.org/10.1001/jama.2017.5427 CrossRef

29.

Anker SD, Kirwan BA, van Veldhuisen DJ et al (2018) Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 20(1):125–133. https://doi.org/10.1002/ejhf.823 CrossRef

30.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720 CrossRef

31.

Inzucchi SE, Zinman B, Fitchett D et al (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41(2):356–363. https://doi.org/10.2337/dc17-1096 CrossRef

32.

Mahaffey KW, Neal B, Perkovic V et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation 137(4):323–334. https://doi.org/10.1161/CIRCULATIONAHA.117.032038 CrossRef

33.

Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389 CrossRef

34.

McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa1911303 CrossRef

35.

Kober L, Thune JJ, Nielsen JC et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375(13):1221–1230. https://doi.org/10.1056/NEJMoa1608029 CrossRef

36.

Shen L, Jhund PS, Petrie MC et al (2017) Declining risk of sudden death in heart failure. N Engl J Med 377(1):41–51. https://doi.org/10.1056/NEJMoa1609758 CrossRef

37.

Pocock SJ, Collier TJ (2018) Critical appraisal of the 2018 ACC scientific sessions late-breaking trials from a statistician’s perspective. J Am Coll Cardiol 71(25):2957–2969. https://doi.org/10.1016/j.jacc.2018.04.015 CrossRef

38.

Olgin JE, Pletcher MJ, Vittinghoff E et al (2018) Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med 379(13):1205–1215. https://doi.org/10.1056/NEJMoa1800781 CrossRef

39.

Cleland JG, Abraham WT, Linde C et al (2013) An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 34(46):3547–3556. https://doi.org/10.1093/eurheartj/eht290 CrossRef

40.

Abraham WT, Kuck KH, Goldsmith RL et al (2018) A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. Jacc Heart Fail 6(10):874–883. https://doi.org/10.1016/j.jchf.2018.04.010 CrossRef

41.

Mehra MR, Goldstein DJ, Uriel N et al (2018) Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med 378(15):1386–1395. https://doi.org/10.1056/NEJMoa1800866 CrossRef

42.

Pya Y, Maly J, Bekbossynova M et al (2019) First human use of a wireless coplanar energy transfer coupled with a continuous-flow left ventricular assist device. J Heart Lung Transplant 38(4):339–343. https://doi.org/10.1016/j.healun.2019.01.1316 CrossRef

43.

Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210 CrossRef

44.

Marrouche NF, Brachmann J, Andresen D et al (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378(5):417–427. https://doi.org/10.1056/NEJMoa1707855 CrossRef

45.

Packer M, Kowey PR (2018) Building castles in the sky. Circulation 138(8):751–753. https://doi.org/10.1161/CIRCULATIONAHA.118.034583 CrossRef

46.

Packer DL, Mark DB, Robb RA et al (2019) Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 321(13):1261–1274. https://doi.org/10.1001/jama.2019.0693 CrossRef

47.

Brignole M, Pokushalov E, Pentimalli F et al (2018) A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 39(45):3999–4008. https://doi.org/10.1093/eurheartj/ehy555 CrossRef

48.

Sannino A, Smith RL 2nd, Schiattarella GG et al (2017) Survival and cardiovascular outcomes of patients with secondary mitral regurgitation: a systematic review and meta-analysis. JAMA Cardiol 2(10):1130–1139. https://doi.org/10.1001/jamacardio.2017.2976 CrossRef

49.

Feldman T, Foster E, Glower DD et al (2011) Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364(15):1395–1406. https://doi.org/10.1056/NEJMoa1009355 CrossRef

50.

Stone GW, Lindenfeld J, Abraham WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379(24):2307–2318. https://doi.org/10.1056/NEJMoa1806640 CrossRef

51.

Obadia JF, Messika-Zeitoun D, Leurent G et al (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 379(24):2297–2306. https://doi.org/10.1056/NEJMoa1805374 CrossRef

52.

Senni M, Adamo M, Metra M et al (2019) Treatment of functional mitral regurgitation in chronic heart failure: can we get a ‘proof of concept’ from the MITRA-FR and COAPT trials? Eur J Heart Fail 21(7):852–861. https://doi.org/10.1002/ejhf.1491 CrossRef

53.

Kang DH, Park SJ, Shin SH et al (2019) Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 139(11):1354–1365. https://doi.org/10.1161/CIRCULATIONAHA.118.037077 CrossRef

54.

Van Spall HGC, Rahman T, Mytton O et al (2017) Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail 19(11):1427–1443. https://doi.org/10.1002/ejhf.765 CrossRef

55.

Angermann CE, Stork S, Gelbrich G et al (2012) Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study. Circ Heart Fail 5(1):25–35. https://doi.org/10.1161/CIRCHEARTFAILURE.111.962969 CrossRef

56.

Jonkman NH, Westland H, Groenwold RH et al (2016) Do self-management interventions work in patients with heart failure? An individual patient data meta-analysis. Circulation 133(12):1189–1198. https://doi.org/10.1161/CIRCULATIONAHA.115.018006 CrossRef

57.

https://www.g-ba.de/downloads/39-261-3299/2018-04-19_DMP-A-RL_Aenderung-Anlage-2-und-5_Ergaenzung-Herzinsuffizienz_BAnz.pdf, aufgerufen am 13. Nov. 2019

58.

Koehler F, Koehler K, Deckwart O et al (2018) Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet 392(10152):1047–1057. https://doi.org/10.1016/S0140-6736(18)31880-4 CrossRef

59.

Koehler P, Stecher M, Cornely OA et al (2019) Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect 25(10):1200–1212. https://doi.org/10.1016/j.cmi.2019.04.024 CrossRef

60.

Angermann CE, Rosenkranz S (2018) Telemonitoring and pulmonary artery pressure-guided treatment of heart failure. Internist 59(10):1041–1053. https://doi.org/10.1007/s00108-018-0495-1 CrossRef

61.

Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377(9766):658–666. https://doi.org/10.1016/S0140-6736(11)60101-3 CrossRef

62.

Abraham WT, Stevenson LW, Bourge RC et al (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387(10017):453–461. https://doi.org/10.1016/S0140-6736(15)00723-0 CrossRef

63.

Adamson PB, Abraham WT, Bourge RC et al (2014) Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7(6):935–944. https://doi.org/10.1161/CIRCHEARTFAILURE.113.001229 CrossRef

64.

Desai AS, Bhimaraj A, Bharmi R et al (2017) Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol 69(19):2357–2365. https://doi.org/10.1016/j.jacc.2017.03.009 CrossRef

65.

Angermann CE, Assmus B, Anker SD et al (2018) Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clin Res Cardiol 107(11):991–1002. https://doi.org/10.1007/s00392-018-1281-8 CrossRef

66.

Hindricks G, Taborsky M, Glikson M et al (2014) Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 384(9943):583–590. https://doi.org/10.1016/S0140-6736(14)61176-4 CrossRef

67.

Ertl G, Angermann CE, Bekeredjian R et al (2016) 2016 Empfehlung Aufbau und Organisation von Herzinsuffizienz-Netzwerken (HF-NETs) und Herzinsuffizienz-Einheiten („Heart Failure Units“, HFUs) zur Optimierung der Behandlung der akuten und chronischen Herzinsuffizienz. Kardiologe 10:222. https://doi.org/10.1007/s12181-016-0072-6 CrossRef

Titel: Diagnostik und Therapie der chronischen Herzinsuffizienz
Update 2020
verfasst von: Prof. Dr. Gülmisal Güder
Prof. Dr. Georg Ertl
Prof. Dr. Christiane E. Angermann
Publikationsdatum: 03.02.2020
Verlag: Springer Medizin
Schlagwörter: Herzinsuffizienz
Diagnostik in der Kardiologie
Herzerkrankungen und Komorbidität
Herzinfarkt
Herzinsuffizienz in der Hausarztpraxis
ICD-Implantation
Interventionelle Verfahren in der Kardiologie
Erschienen in: Herz
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-04877-z

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten